Lakewood-Amedex Biotherapeutics lists on Nasdaq Capital Market under LABT ticker - LABT News | RalliesLakewood-Amedex Biotherapeutics lists on Nasdaq Capital Market under LABT ticker
L
LABT• Share authorization and remaining Series C conversions
- A Sept. 18 registration statement covered up to 4,512,400 common shares issuable from remaining Series C conversions, enabling staged sales.
- Shareholders vote Sept. 22 on raising authorized common shares to 100 million, with reverse-split authority up to 1-for-20 if needed for Nasdaq.
Nasdaq Capital Market listing and capital structure changes
- Lakewood-Amedex Biotherapeutics shifted its stock listing to the Nasdaq Capital Market under ticker LABT on April 23, 2026.
- The listing followed a $7.5 million private placement of Series C Convertible Preferred Stock, aimed at supporting clinical development.
- Earlier preferred stock and convertible notes converted into common stock in connection with the Nasdaq listing, simplifying the capital structure.
•
